Company Position Country
Abolis President France
How does fermentation innovation evolve towards value generation?

Cyrille Pauthenier, PhD. graduated from École Normale Supérieure (ENS) in Paris, Master in System and Synthetic Biology in Paris-Saclay University and a doctorate in metabolic engineering at Paris-Saclay University. In 2014, he co-founded Abolis Biotechnologies, with the aim of bringing state-of-the-art methodologies in metabolic engineering for the development of new micro-organism capable of producing any arbitrary chemical molecules using fermentation of renewable resources.

Abolis Biotechnologies is now a 20 people company, which actively develops software solutions for discovering new enzymes and pathways; operates a large biology lab which develops molecule-producing strains and custom genetic tools for a large variety of chassis strains; develops a robotic platform to assemble genes at high throughput; operates a cutting edge analytic and mass spectrometry laboratory and a small fermentation platform to scale the processes up to 20L.

The company is currently developing a lot of different technology from pathway prototyping to optimized industrial strain construction in house and partners with scale-up and DSP experts in order to cover the entire value chain. Abolis aims at offering to the industry by 2020 a complete service in which, for any arbitrary molecule, we find a metabolic route, demonstrate its functionality and bring the project from the idea to a robust industrial process.